Literature DB >> 23897773

Biosimilars to treat inflammatory arthritis: the challenge of proving identity.

Jonathan Kay, Josef S Smolen.   

Abstract

Entities:  

Keywords:  Ankylosing Spondylitis; Anti-TNF; Pharmacokinetics; Rheumatoid Arthritis; Treatment

Mesh：

Substances：

Year:  2013        PMID： 23897773     DOI： 10.1136/annrheumdis-2012-203198

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  14 in total

Review 1.  [Biosimilars in rheumatology. Development and results of clinical trials].

Authors:  R Alten
Journal:  Z Rheumatol       Date:  2015-10       Impact factor: 1.372

Review 2.  Differentiating biosimilarity and comparability in biotherapeutics.

Authors:  Valderilio Azevedo; Brian Hassett; João Eurico Fonseca; Tatsuya Atsumi; Javier Coindreau; Ira Jacobs; Ehab Mahgoub; Julie O'Brien; Ena Singh; Steven Vicik; Brian Fitzpatrick
Journal:  Clin Rheumatol       Date:  2016-10-12       Impact factor: 2.980

Review 3.  Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.

Authors:  Krisztina B Gecse; Péter L Lakatos
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

4.  Degree of prescriber's knowledge about variability in biological drugs "innovators" in manufacturing process.

Authors:  Lucía Jiménez-Pichardo; Rocío Gázquez-Pérez; Jesús Francisco Sierra-Sánchez
Journal:  Eur J Clin Pharmacol       Date:  2017-12-15       Impact factor: 2.953

5.  [Revised version of the statement by the DGRh on biosimilars-update 2017].

Authors:  J Braun; H M Lorenz; U Müller-Ladner; M Schneider; H Schulze-Koops; Ch Specker; A Strangfeld; U Wagner; T Dörner
Journal:  Z Rheumatol       Date:  2018-02       Impact factor: 1.372

Review 6.  The changing landscape of biosimilars in rheumatology.

Authors:  Thomas Dörner; Vibeke Strand; Paul Cornes; João Gonçalves; László Gulácsi; Jonathan Kay; Tore K Kvien; Josef Smolen; Yoshiya Tanaka; Gerd R Burmester
Journal:  Ann Rheum Dis       Date:  2016-03-08       Impact factor: 19.103

Review 7.  Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.

Authors:  Eduardo Mysler; Carlos Pineda; Takahiko Horiuchi; Ena Singh; Ehab Mahgoub; Javier Coindreau; Ira Jacobs
Journal:  Rheumatol Int       Date:  2016-02-27       Impact factor: 2.631

Review 8.  Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example.

Authors:  Zhihong Lai; Anna La Noce
Journal:  RMD Open       Date:  2016-02-05

9.  A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

Authors:  Jung-Yoon Choe; Nenad Prodanovic; Jaroslaw Niebrzydowski; Ivan Staykov; Eva Dokoupilova; Asta Baranauskaite; Roman Yatsyshyn; Mevludin Mekic; Wieskawa Porawska; Hana Ciferska; Krystyna Jedrychowicz-Rosiak; Agnieszka Zielinska; Jasmine Choi; Young Hee Rho; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2015-08-28       Impact factor: 19.103

10.  Biosimilars in rheumatology: what the clinician should know.

Authors:  Gilberto Castañeda-Hernández; Rodrigo González-Ramírez; Jonathan Kay; Morton A Scheinberg
Journal:  RMD Open       Date:  2015-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.